Notable Labs Ltd (NTBL): תחזית צמיחת רווח נקי למניה לשנה הבאה

Notable Labs, Ltd. (NTBL) is implementing AI to personalize therapy for hematological diseases. The GURU.Markets platform reflects analyst expectations for N+1 profit dynamics, where the indicator reached -47.00, capturing market optimism. Notable Labs, Ltd. (NTBL) generates revenue through predictive live-cell testing to select effective chemotherapy. Growth prospects rely on the automation of cell screening to accurately forecast patient response.

Investors assess business resilience through future revenue dynamics, utilizing this indicator as an aggregated forecast for next year's earnings per share (EPS) change. By analyzing expectations for net earnings per share, one can evaluate the impact of clinical validation costs for the Notable Labs, Ltd. (NTBL) IT platform and the risks of partner R&D budget cuts on the company's final profitability.